UNSPSC 51281508: Morinamide or morphazinamide or morinamid

This classification denotes an antitubercular agent with the molecular formula C10H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8CFL28PA3W, chemically known as pyrazinecarboxamide, n-(morpholinomethyl)- but generally known as morinamide, which bears US NIH Compound Identifier 70374. European Medicines Agency schedules Morinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09067MIG. The term MORINAMIDE is an International Non-Proprietary Name.

World Health Organization schedules morinamide in its Anatomical Therapeutic Chemical (ATC) Classification. MORINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: C1COCCN1CNC(=O)C2=NC=CN=C2.

UNSPSC 51281508 Morinamide or morphazinamide or morinamid is a Commodity code intended to cover a specific pharmaceutical active ingredient, but state and local procurement activity under this code does not align with the nominal scope — recent opportunities instead show purchases of common antimicrobial and emergency-response pharmaceuticals including doxycycline, ciprofloxacin, and naloxone, as well as drug deactivation systems. The issuing bodies soliciting under this code include state health departments and county governments pursuing supply contracts to support public health and emergency-response missions. Purchasing typically occurs through cooperative agreements and consortium piggyback contracts as well as direct competitive bidding, with multi-year initial terms and renewal options standard in the activity.

Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, totaling $2,999,999.11 over the life of the contract for the supply of Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets under an Invitation for Bid process. Seminole County, Florida released an IFB on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, though this opportunity shows a discrepancy between posting date (June 30, 2026) and listed response deadline (July 26, 2023). The code shows recent activity in Florida and Illinois, with cooperative purchasing vehicles and direct county procurement both in use; however, the mismatch between the code's stated scope and the pharmaceuticals actually being bought warrants verification of the code assignment before pursuing opportunities under this classification.